论文部分内容阅读
目的:探讨特布他林联合布地奈德吸入治疗慢性阻塞性肺病急性加重期(AECOPD)患者的临床疗效及安全性。方法:60例老年AECOPD患者随机分2组,对照组30例进行抗感染、平喘、化痰、吸氧等常规治疗,治疗组30例在常规的基础上增加特布他林5 mg联合布地奈德1 mg雾化吸入,bid,观察两组患者用药5~7 d的临床症状、肺功能指标、相关血气变化及药品不良反应。结果:治疗后,两组FEV_、FEV_占预计值百分比、FVC、PEF,以及PaO_2、PaCO_2、SaO_2等指标等指标均较治疗前明显改善(P<0.05或0.01),且治疗组改善程度优于对照组(P<0.05或0.01)。治疗组主要症状体征消失时间较对照组明显缩短(P<0.01),总有效率明显高于对照组(P<0.05)。结论:特布他林联合布地奈德雾化吸入治疗AECOPD患者安全有效。
Objective: To investigate the clinical efficacy and safety of terbutaline combined with budesonide in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods: Sixty elderly patients with AECOPD were randomly divided into two groups. The control group received routine therapy such as anti-infective, antiasthmatic, phlegm-phlegm and oxygen inhalation. 30 patients in the treatment group were given conventional terbutaline 5 mg budesonide Ned 1 mg aerosol inhalation, bid, observed two groups of patients medication 5-7 d clinical symptoms, lung function, blood gas related changes and adverse drug reactions. Results: After treatment, the indexes of FEV_, FEV_in the predicted value, FVC, PEF, PaO_2, PaCO_2 and SaO_2 in the two groups were significantly improved (P <0.05 or 0.01), and the improvement in the treatment group was superior In the control group (P <0.05 or 0.01). The disappearance time of the main symptoms and signs of the treatment group was significantly shorter than that of the control group (P <0.01), and the total effective rate was significantly higher than that of the control group (P <0.05). Conclusion: Terbutaline combined with budesonide inhalation is safe and effective in patients with AECOPD.